MiMedx: Reimbursement Hurdles Mask A Compelling Valuation Opportunity (Rating Upgrade) [Seeking Alpha]
MiMedx Group, Inc (MDXG)
Last mimedx group, inc earnings: 4/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=213465&p=irol-irhome
Company Research
Source: Seeking Alpha
Despite reimbursement risks, MiMedx's robust clinical evidence and leading market share position it well for future regulatory and market tailwinds. My DCF analysis suggests MDXG is undervalued by 17%, offering asymmetric upside potential, though not deeply mispriced at current levels. Given profitability, evidence-backed products, and valuation, I upgrade MDXG to Buy, but highlight it as a high-risk/high-reward opportunity best suited for barbell portfolios. Minwan/iStock via Getty Images MiMedx Stock Revisited: Transition Continues, But Value Emerges MiMedx's stock ( NASDAQ: MDXG ) has underperformed the broader markets, with returns of -7% versus 50.6% for the S&P 500 since my last evaluation in October This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own op
Show less
Read more
Impact Snapshot
Event Time:
MDXG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDXG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDXG alerts
High impacting MiMedx Group, Inc news events
Weekly update
A roundup of the hottest topics
MDXG
News
- MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro [Yahoo! Finance]Yahoo! Finance
- MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In VitroGlobeNewswire
- MiMedx Group (NASDAQ:MDXG) had its price target lowered by analysts at Mizuho from $12.00 to $10.00. They now have an "outperform" rating on the stock.MarketBeat
- ?????????? - ??????????????????2026-2035? [CNET News]CNET News
- MiMedx (MDXG) Just Flashed Golden Cross Signal: Do You Buy? [Yahoo! Finance]Yahoo! Finance
MDXG
Earnings
- 10/29/25 - Beat
MDXG
Sec Filings
- 11/10/25 - Form 4
- 11/6/25 - Form 144
- 10/29/25 - Form 8-K
- MDXG's page on the SEC website